A Disintegrin and Metalloenzyme (ADAM) 17 Activation Is Regulated by α5β1 Integrin in Kidney Mesangial Cells by Gooz, Pal et al.
A Disintegrin and Metalloenzyme (ADAM) 17 Activation
Is Regulated by a5b1 Integrin in Kidney Mesangial Cells
Pal Gooz
1, Yujing Dang
1, Shigeki Higashiyama
2, Waleed O. Twal
3, Courtney J. Haycraft
4, Monika Gooz
1*
1Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America, 2Department of Biochemistry and Molecular
Genetics, Center for Regenerative Medicine CEREM, Ehime University Graduate School of Medicine, Ehime, Japan, 3Department of Regenerative Medicine and Cell
Biology, Medical University of South Carolina, Charleston, South Carolina, United States of America, 4College of Dental Medicine, Craniofacial Biology, Medical University
of South Carolina, Charleston, South Carolina, United States of America
Abstract
Background: The disintegrin and metalloenzyme ADAM17 participates in numerous inflammatory and proliferative
diseases, and its pathophysiological role was implicated in kidney fibrosis, polycystic kidney disease and other chronic
kidney diseases. At present, we have little understanding how the enzyme activity is regulated. In this study we wanted to
characterize the role of a5b1 integrin in ADAM17 activity regulation during G protein-coupled receptor (GPCR) stimulation.
Methodology/Principal Findings: We showed previously that the profibrotic GPCR agonist serotonin (5-HT) induced kidney
mesangial cell proliferation through ADAM17 activation and heparin-binding epidermal growth factor (HB-EGF) shedding. In
the present studies we observed that in unstimulated mesangial cell lysates a5b1 integrin co-precipitated with ADAM17
and that 5-HT treatment of the cells induced dissociation of a5b1 integrin from ADAM17. Using fluorescence
immunostaining and in situ proximity ligation assay, we identified the perinuclear region as the localization of the
ADAM17/a5b1 integrin interaction. In cell-free assays, we showed that purified a5b1 integrin and b1 integrin dose-
dependently bound to and inhibited activity of recombinant ADAM17. We provided evidence that the conformation of the
integrin determines its ADAM17-binding ability. To study the effect of b1 integrin on ADAM17 sheddase activity, we
employed alkaline phosphatase-tagged HB-EGF. Overexpression of b1 integrin lead to complete inhibition of 5-HT-induced
HB-EGF shedding and silencing b1 integrin by siRNA significantly increased mesangial cells ADAM17 responsiveness to 5-
HT.
Conclusions/Significance: Our data show for the first time that b1 integrin has an important physiological role in ADAM17
activity regulation. We suggest that regulating a5b1 integrin binding to ADAM17 could be an attractive therapeutic target
in chronic kidney diseases.
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Introduction
ADAM17, one of the most intensively studied member of the
disintegrin and metalloenzyme family was identified as the protease
which cleaves the cell-surface-bound form of the inflammatory
cytokine, pro-tumor necrosis factor (TNF)a [1,2]. Since then, a
wealth of information has been gathered about the enzyme
function: ADAM17 is indispensable to normal development [3,4],
and it has a fundamental role in inflammation through shedding of
TNFa [1,2] and its receptors, TNFRI and II [5], and processing cell
adhesion molecules which initiate leukocyte transmigration through
the vascular wall [6]. ADAM17 also has an important role in cell-
fate decisions by shedding the ectodomain of Notch [7]. ADAM17
participates in protein ectodomain shedding of epidermal growth
factor (EGF) receptor ligands such as heparin-binding EGF (HB-
EGF), transforming growth factor (TGF)a, and amphiregulin
which, in turn, activate the EGF receptor (EGFR) and initiate
downstream signaling events leading to cell proliferation, migration,
or apoptosis (see recent review [8]). The role of ADAM17 in the so-
called ‘‘triple membrane spanning signaling’’ (TMSS) was also
investigated: agonists of G protein-coupled receptors (GPCRs) were
shown to trans-activate receptor tyrosine kinases (RTK), including
the EGFR, by activating ADAM17 and leading to growth factor
shedding (for review see [9]). Our group showed previously that
bradykinin changes glomerular permeability through ADAM17
activation-induced epiregulin shedding and EGFR transactivation
[10]. We also showed that the pro-fibrotic GPCR agonist serotonin
(5-HT) induces proliferation of kidney mesangial cells through
EGFR transactivation. We identified ADAM17 as the sheddase
enzyme that processes the EGFR ligand HB-EGF during 5-HT-
inducedTMSS inmesangialcells[11]. Further,we alsoshowed that
ADAM17 activity is necessary for VEGF-induced MMP-2
activation and angiogenesis [12]. All of the above described
processes: inflammation, apoptosis, cell proliferation, and angio-
genesis have important pathophysiological role in the development
of chronic kidney diseases [13,14,15,16]. Since ADAM17 has a
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understand how ADAM17 activity is regulated.
Tissue inhibitor of metalloproteinase (TIMP)-3 was identified by
current studies as an important negative regulator of ADAM17
activity. Loss of TIMP-3 in mice increased ADAM17 activity and
augmented development of interstitial nephrosis and nephritis
after unilateral ureteral obstruction [17]. Another interesting study
showed that TIMP-3 knockout animals developed hepatic steatosis
and adipose tissue inflammation possibly through ADAM17
upregulation [18]. Higher ADAM17 activity also contributed to
high fat diet-induced glucose intolerance and insulin resistance in
the same animal model [19].
ADAM17 has a multidomain structure: other than a prodo-
main, it has a catalytic domain, a disintegrin domain, a
transmembrane domain, and a cytoplasmic domain. It was shown
previously that phosphorylation of the cytoplasmic domain can
regulate the enzyme activity; however, these reports are somewhat
controversial [20,21]. The disintegrin domain of the ADAM
enzymes is related to snake venom disintegrins and based on their
structural similarities it was implicated in binding the cell adhesion
receptors integrins. So far, several ADAMs were shown to bind
integrins: the recombinant disintegrin fragment of ADAM15
promoted attachment of cells expressing avb3 and a5b1integrins,
both in an Arg-Gly-Asp-(RGD)-dependent and independent
manner, and a9b1 integrin was shown to bind ADAM1, 2, 3, 7,
9, 12, 15, 28, 33 (detailed review on ADAM-integrin binding [22]).
Further, the recombinant ectodomain fragment of ADAM17 was
shown to mediate cellular adhesion of a5b1 integrin-expressing
cells on a plastic surface and to bind purified a5b1 integrin [23].
Also, cellular ADAM17 was shown to co-localize with overex-
pressed a5b1 integrin in migrating HeLa cells [23]. In these
studies, the ADAM-integrin interaction was chiefly explored in the
context of cell adhesion, and ADAMs were often regarded as
integrin counter-receptors. At this time, we have no data on how
integrin binding affects the enzymatic activity of ADAMs.
We showed recently, that ADAM17 co-precipitated with a5b1
integrin in gastric epithelial carcinoma cells [24]. However, we
had no data regarding the exact function of the ADAM17/
integrin binding, especially whether ADAM17 binding to a5b1
integrin (or any other integrin) regulated the enzyme activity.
Moreover, we were uncertain whether a physiological stimulus
such as GPCR activation, which results in subsequent activation of
ADAM17, affects ADAM17 integrin binding.
In this study, we provide evidence that a5b1 integrin binds to
ADAM17 in resting mesangial cells using co-immunoprecipitation
and fluorescence co-localization experiments. We quantify the
extent of endogenous protein interaction and confirm the location
of the ADAM/integrin interaction by fluorescence in situ proximity
ligation assay. Furthermore, we demonstrate - for the first time -
that a5b1 integrin-binding regulates ADAM17 enzymatic activity
both in a cell-free system and in mesangial cells in vivo. We show
that GPCR stimulation leads to ADAM17/a5b1 integrin complex
dissociation, which releases the enzyme activity and contributes to
HB-EGF shedding in mesangial cells. Our data suggest that
regulating a5b1 integrin binding to ADAM17 could be an
attractive therapeutic target in chronic kidney diseases.
Results
ADAM17 binds to a5b1 integrin in mesangial cells and
GPCR stimulation decreases ADAM17 binding to a5b1
integrin
To test whether ADAM17 binds to a5b1 integrin in rat kidney
mesangial cells we performed immunoprecipitation. Control and
5-HT-treated (1 mM for 10 min) mesangial cell lysates were
incubated with ADAM17 antibody. Immunoprecipitated com-
plexes were analyzed by SDS-PAGE followed by Western blotting
to visualize the presence of integrins. We found that a5b1 integrin
co-precipitated with ADAM17 (Figure 1A). Interestingly, during
our experiment we also observed that significantly less integrin co-
precipitated with ADAM17 in 5-HT-treated cell lysate than in
control unstimulated cells lysate (Figure 1A) suggesting that 5-HT
induced dissociation of the ADAM17/a5b1 integrin complex. As
negative control we used normal mouse IgG (Figure 1A) and equal
loading of immunoprecipitated ADAM17 was confirmed by re-
probing the b1 integrin blot for ADAM17 (Figure 1B).
ADAM17 co-localizes with a5b1 integrin in mesangial
cells
To understand the localization of ADAM17/a5b1 integrin
interaction we performed immunofluorescence studies. First, we
tested the ADAM17 and a5b1 integrin antibodies by a
‘‘traditional’’ fluorescence immunocytochemistry. Quiescent cells
were incubated in serum-free medium with or without 1 mMo f5 -
HT and immunostaining for ADAM17 and a5b1 integrin were
performed as detailed in ‘‘Material and Methods’’. We found that
ADAM17 co-localized with the integrin in the perinuclear region
of unstimulated cells (Figure 2A upper panels, arrows). After 5-HT
stimulation the intensity of both ADAM17 and a5b1 integrin
immunopositive signals were decreased in the perinuclear region
and rather distributed across throughout the cytoplasm and in the
plasma membrane (Figure 2A lower panels, arrows).
Next, we employed the Duolink in situ proximity ligation assay
(PLA) in order to confirm the co-localization and to quantify the
ADAM17/a5b1 integrin interaction. The results obtained with
PLA corresponded very well with the results of the immunoflu-
orescence staining. The signals were localized in the perinuclear
Figure 1. ADAM17 co-precipitates with a5b1 integrin and
dissociates from the integrin during GPCR stimulation. (A)
Control (2) and 1 mM 5-HT stimulated (+) mesangial cell lysates were
immunoprecipitated (IP) with either ADAM17 antibody or Ig control (Ig
C), resolved on 3–8% Tris-acetate gel and probed for the presence of b1
integrin and a5 integrin by Western blotting. (B) ADAM17 blot shows
that equal amount of ADAM17 were precipitated from each sample.
Arrows point to specific and non-specific (NS) bands. One representa-
tive example out of four experiments is shown.
doi:10.1371/journal.pone.0033350.g001
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HT-treated cells. Since PLA signal only forms if the two different
antibodies(ADAM17anda5b1integrinantibodies) bind toproteins
that are in close proximity (Figure 2, cartoon), this assay confirmed
that ADAM17 forms a complex with a5b1 integrin, and that this
complex disassemblesupon 5-HT stimulation. Quantitative analysis
showed that compared to control cells about 13% of the complexes
remained after 5-HT stimulation (Figure 2B).
Experiments in cell-free systems show direct interaction
of recombinant ADAM17 with a5b1 integrin
To investigate whether ADAM17 can bind a5b1 integrin
directly, even without the cellular environment and/or help of
adaptor molecules, we performed the following assays with
recombinant ADAM17 and purified a5b1 integrin/recombinant
b1 integrin in cell free systems:
First, to confirm that ADAM17 is capable of direct integrin
binding and to complement our co-immunoprecipitation studies,
we employed capture-ELISA. Plates pre-coated with a5b1 integrin
antibody were incubated with purified a5b1 integrin, and anti-b1
integrin pre-coated plates were incubated with recombinant b1
integrin. Increasing concentrations of His-tagged recombinant
human ADAM17 (0–20 mg/ml) were then added to both plates
and the amount of captured ADAM17 was measured. As shown in
Figure 3A both purified a5b1 integrin and recombinant b1
integrin were able to bind ADAM17 dose dependently. As
negative control BSA-coated surface was used, that showed only
negligible ADAM17 binding. These data suggest that not only
a5b1 integrin but also b1 integrin alone is capable of ADAM17
binding.
To confirm our data we employed surface plasmon resonance
and strong binding was observed between the ADAM17 that was
Figure 2. Co-localization of ADAM17 and a5b1 integrin in rat mesangial cells. Control (C) and 1 mM 5-HT -stimulated mesangial cell were
fixed, permeabilized, and (A) co-immunostained using ADAM17 antibody (green) and b1 integrin antibody (red) as indicated in ‘‘Material and
Methods’’. Arrows indicate co-localization of ADAM17 and a5b1 integrin immunopositive areas (yellow). For the negative controls we omitted the
primary antibodies and used PBS followed by secondary antibodies. (B) Parallel samples were incubated with oligonucleotide-labeled PLA probes
after incubation with primary antibodies. PLA signals as fluorescence dots were imaged and quantified. As negative control we used either ADAM17
or a5b1 integrin antibody alone followed by the oligonucleotide-labeled PLA probes. Cartoon explains binding of the fluorescence detection reagent
only to antibodies in close proximity; **p,0.01. Representative examples out of three experiments are shown.
doi:10.1371/journal.pone.0033350.g002
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integrin that was injected over the chip (data not shown).
Purified a5b1 integrin and recombinant b1 integrin
inhibit recombinant ADAM17 activity
After confirming that ADAM17 can directly bind to a5b1
integrin, we sought evidence that direct binding of the integrin
regulates ADAM17 enzymatic activity. Recombinant ADAM17
was combined with different molar concentrations of recombinant
b1 integrin or with purified, octyl-b-glucoside (OG) extracted
a5b1 integrin at a 1:1 and 1:10 molar ratio in OG containing
buffer. Enzyme activity was measured by addition of a quenched
fluorogenic ADAM17 peptide substrate. In this assay, substrate
cleavage results in separation of the quencher from the
fluorophore, and thus increases the fluorescence intensity of the
peptide substrate. Figure 3B shows that both a5b1 integrin and b1
integrin decreased ADAM17 enzymatic activity dose dependently
and that maximum inhibition was achieved by 1:10 molar ratio of
integrins to ADAM17.
b1 integrin regulates HB-EGF shedding by ADAM17 in
mesangial cells
We showed previously that 5-HT stimulation induced AD-
AM17-dependent HB-EGF shedding in mesangial cells [11]. In
the following experiments, we wanted to confirm that b1 integrin
regulates ADAM17 sheddase activity. For this purpose, we
employed a sensitive method to study ADAM17 activity: we
transfected mesangial cells with alkaline phosphatase (AP)-tagged
HB-EGF. Two days after transfection, cells were stimulated with
1 mM 5-HT for 1–3 hours as described previously [11], and
growth factor release was quantified by measuring the AP activity
from the cell conditioned media. We found that 5-HT induced
time-dependent increases in AP activity in the medium as an
indicator of increased HB-EGF shedding (Figure 4A). With these
experiments, we validated AP-HB-EGF as a tool for studying
ADAM17 activity in our cell system. As we observed the biggest
difference in 5-HT-induced growth factor shedding compared to
control at 1 hour (2.6-fold), we chose this timepoint in subsequent
experiments.
Since we hypothesized that b1 integrin inhibits ADAM17
activity in mesangial cells we aimed to knock down b1 integrin and
study changes in basal and 5-HT-stimulated ADAM17 activity.
Mesangial cells were transfected with either (1) AP-HB-EGF
construct and a control, non-targeting siRNA (nt-RNA) or (2) AP-
HB-EGF construct and b1 integrin silencing RNA (b1-siRNA).
Two days after transfection, we stimulated the cells with 5-HT
(1 mM) for 1 h and measured AP activity from the cell media as
described above. Figure 4B shows that b1 integrin silencing
resulted in a moderate, but significant increase in basal ADAM17
activity, and it significantly enhanced 5-HT-induced HB-EGF
shedding. The Western blot insert in Figure 4B shows that we
achieved almost complete inhibition of b1 integrin expression with
our gene silencing approach.
Next, we transfected a b1 integrin-expressing vector into
mesangial cells to study whether we can inhibit 5-HT-induced
ADAM17 activation. We co-transfected our cells with the following:
(1) AP-HB-EGF construct and a control, GFP-expressing vector
(Co-DNA) or (2) AP-HB-EGF construct and b1 integrin expression
vector (b1-plasmid). Two days after transfection, we stimulated the
cells with 5-HT (1 mM) for 1 h and measured AP activity from the
cell media. Figure 4C shows that b1 integrin overexpression did not
significantly influence basal ADAM17 sheddase activity; however, it
completely inhibited 5-HT induced AP-HB-EGF shedding. Suc-
cessful overexpression of b1 integrin was confirmed by Western
blotting (see insert in Figure 4C).
Integrin activity status regulates ADAM17/a5b1 integrin
complex formation
Conformation of recombinant and purified protein can differ
from their three-dimensional in vivo structure. Since in the cell
Figure 3. Cell free assays show ADAM17 binding to a5b1
integrin and changes in ADAM17 activity. (A) Recombinant
ADAM17 binds purified a5b1 integrin and recombinant b1 integrin in
a cell free binding assay. Plates pre-coated with antibodies against a5b1
integrin or b1 integrin were incubated with purified a5b1 integrin or
with b1 recombinant integrin, individually. Recombinant ADAM17 was
then added at the indicated concentrations and ADAM17 binding was
measured using a colorimetric assay at 450 nm as described in
Methods. Data are expressed as mean6S.D. *p,0.05, **p,0.01 vs
control; data from 4 experiments with 3 parallels/each condition are
shown. (B) Purified a5b1 integrin and recombinant b1 integrin decrease
ADAM17 enzymatic activity. Recombinant ADAM17 (10 ng/ml) was
incubated alone or together with either purified a5b1 integrin (25 ng/
ml or 250 ng/ml) or with b1 recombinant integrin (12 ng/ml or 120 ng/
ml), in OG buffer in the presence of a quenched fluorogenic ADAM17
substrate. Enzyme activity was expressed as the rate of change of
relative fluorescence units (DRFUs
21); *p,0.05, **p,0.01 vs control;
data from four experiments with eight parallels/each condition are
shown.
doi:10.1371/journal.pone.0033350.g003
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complete inhibition of ADAM17 activity by the integrins, we
hypothesized that conformation of b1 integrin can play an
important role in its ADAM17 binding. Therefore, we investigated
whether the presence of the divalent cation Mn
2+, which is known
to activate integrin conformation, affects the ADAM17/a5b1
integrin complex formation. Mesangial cells were incubated in
control or in 1 mM Mn
2+ containing medium for 2 minutes then
lyzed in OG lysis buffer. Protein complexes were immunoprecip-
itated with ADAM17 antibody. Immunocomplexes were analyzed
in SDS-PAGE followed by Western blotting for a5 and b1 integrin
and ADAM17. As shown in Figure 5A, Mn
2+2-treatment induced
a decrease in the ADAM17/a5b1 integrin complex. At the same
time, using AP-HB-EGF transfected cells we found that Mn
2+2-
treatment induced a more than 2-fold increase in ADAM17
sheddase activity (Figure 5B). These data suggest that a5b1
integrin conformation indeed regulates integrin binding to
ADAM17 and thus the enzyme activity.
Discussion
All ADAMs have a disintegrin domain, which is potentially
capable of integrin binding. However, only a limited number of
ADAMs have a catalytically active metalloenzyme domain, which
can process membrane bound proteins. This suggests that in
catalytically inactive ADAMs integrin-binding may be mainly a
Figure 4. Integrin expression regulates ADAM17 sheddase activity. (A) Time-dependent release of alkaline phosphatase (AP)-tagged HB-EGF
by unstimulated (C) and 5-HT stimulated cells. Cells were transfected with AP-HB-EGF expressing plasmid and 2 days after transfection they were
stimulated with 5-HT for the indicated time. AP activity of cell supernatants was determined using Attophos substrate. Data are expressed as
mean6S.D. of fold change in the rate of change of relative fluorescence units; *p,0.05, **p,0.01 vs control at same time point, n=eight
experiments, three parallels/each condition. (B) b1 integrin silencing promotes 5-HT-induced AP-HB-EGF shedding. Cells were transfected with AP-
HB-EGF expression plasmid together with b1 integrin siRNA (b1-siRNA) or a non-targeting (nt2) siRNA. Successful silencing of b1 integrin was
confirmed by resolving the cell lysates on a 4–12% SDS-PAGE and probing for b1 integrin and b-actin (as loading control). Two days after transfection
cells were stimulated with 5-HT for 1 h and AP activity of cell supernatants was determined. (C) b1 integrin overexpression inhibits 5-HT induced AP-
HB-EGF release in mesangial cells. Cells were transfected with AP-HB-EGF and with b1 integrin expressing plasmid (b1-plasmid) or control DNA (Co-
DNA). Successful overexpression of b1 integrin was confirmed by resolving the cell lysates on a 4–12% SDS-PAGE and probing for b1 integrin and b-
actin (as loading control). Two days after transfection cells were stimulated with 5-HT for 1 h and AP activity of cell supernatants was determined.
Activity data are expressed as mean6S.D. of fold change in the rate of change of relative fluorescence units (RFU); *p,0.05, **p,0.01 vs
unstimulated control nt-siRNA or control DNA-transfected cells;
# p,0.05 and
## p,0.01 vs 5-HT stimulated nt-siRNA or DNA-transfected cells;
n=five experiments, three parallels/each condition.
doi:10.1371/journal.pone.0033350.g004
a5b1 Integrin Inhibits ADAM17 Activity
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during the past years [23,25]. However, we have to hypothesize
that in catalytically active ADAMs like ADAM1, 28, 29, 210,
212, 215, 217, 219, 220, 228, 230, 233 integrin binding can
also have another role namely, to regulate the activity of the
ADAM enzymes. Since the disintegrin domain is in close
proximity of the catalytic domain in ADAMs, it is highly possible
that protein binding to the disintegrin domain can have significant
effect on the enzyme activity by, for example, influencing its
substrate binding. Overall, protein-protein interaction can affect
the conformation of the binding partners which itself can lead to
changes in one or both of the binding partners ‘‘activity’’. The
idea, that integrins can regulate ADAM shedding in vivo was
hypothesized by others, too [22]. However, besides data on in vitro
integrin binding and on interaction between overexpressed
integrins and ADAMs, there is still a huge gap in our knowledge
about whether integrins indeed bind and regulate ADAM activity
in vivo.
The immunoprecipitation studies we performed identified a5b1
integrin as the binding partner of ADAM17 in kidney mesangial
cells. One of the most important signaling pathways ADAMs
participate in is the triple membrane spanning signaling: they
mediate crosstalk between GPCRs and receptor tyrosine kinases
(RTKs). This mechanism was first described in 1999 [26], and
since then its role was extensively studied in various pathophys-
iological conditions like heart disease [27], cancer [28], and kidney
fibrosis [29,30]. We have shown previously in an in vitro model of
kidney fibrosis that the GPCR agonist 5-HT induces proliferation
through HB-EGF shedding in mesangial cells [11]. Therefore, we
investigated the effect of 5-HT on ADAM17/a5b1 integrin
assembly. We observed that in mesangial cells GPCR stimulation
induced dissociation of the ADAM17/a5b1 integrin complex.
This suggested that b1 integrin may have an inhibitory effect on
ADAM17 catalytic activity. To our knowledge, this is the first time
that integrins were implicated in ADAM17 activation during
GPCR stimulation and our subsequent experiments were
performed to further confirm this interesting finding.
We used two other detection methods: immunofluorescence co-
localization and in situ proximity ligation to confirm the close
proximity of ADAM17 and a5b1 integrin and to visualize the
location of their interaction in primary culture of mesangial cells.
Co-immunoprecipitation and co-localization studies can suggest
that two molecules are in the same complex however, these
methods cannot show with certainty that the proteins directly
interact with each other. Therefore, we used the Doulink in situ
PLA assay. The great advantage of this method is that (1) it only
shows signal if the two antibodies which we employed recognize
two different proteins which interact (are in close proximity); (2)
because the signal is amplified, it is very sensitive: theoretically
each ‘‘dot’’ shows one interaction between two proteins; but more
importantly (3) the Duolink assay allowed us to compare
ADAM17/a5b1 integrin interactions in control cells to 25-HT
treated cells quantitatively. The PLA data confirmed our
immunofluorescence findings: in untreated cells ADAM17/a5b1
integrin interaction was localized to the perinuclear area. Further,
data analysis showed that compared to control cells after 5-HT
treatment only 13% of the ADAM17/a5b1 integrin interaction
remained and these were scattered inside the cells, similarly as
observed in the confocal immunofluorescence co-localization
study.
Our in vitro binding studies using recombinant ADAM17 and
b1 integrin and purified a5b1 integrin provided evidence that
ADAM17 can bind both a5b1 integrin and b1 integrin directly,
without any adaptor protein. Similar finding on a5b1 integrin
binding to recombinant (Fc-tagged) ADAM17, purified from
COS-1 cells, was previously published [23]. Here we provided
evidence that purified recombinant b1 integrin is also capable of
ADAM17 binding, and most importantly, we showed that both
a5b1 integrin and b1 integrin binding decreased ADAM17
activity. We saw a more complete inhibition of ADAM17 activity
when we increased the molar ratio of ADAM17/integrin to 1:10,
which may suggest that the conformation of the purified integrin
and recombinant ADAM17 is slightly different from their
conformation in the mammalian cellular context. Also, we cannot
rule out that other proteins contribute to the ADAM17/integrin
binding intracellularly which may make the enzyme inhibition
more complete in vivo. We explored the importance of integrin
conformation in a study in which we used MnCl2, a known
Figure 5. Manganase
2+ stimulation decreases association of
ADAM17 to b1 integrin and leads to increased ADAM17
activity. (A) Control and manganese stimulated (1 mM MnCl2 in PIPES
buffer for 2 min) mesangial cell lysates were immunoprecipitated with
ADAM17 antibody. Samples were resolved on a 3–8% Tris-acetate gel
and probed for b1 integrin and a5 integrin by Western blotting.
Immunoblotting for ADAM17 served as loading control. Arrows point to
specific and non-specific (NS) bands. One representative blot out of
three is shown. (B) Mesangial cells were transfected with AP-HB-EGF
construct and stimulated with 1 mM MnCl2 in PIPES buffer. HB-EGF
shedding was expressed as mean6S.D. of fold increase in the rate of
change of relative fluorescence units (RFU); **p,0.01 vs control;
n=three experiments, 6 parallels/each condition.
doi:10.1371/journal.pone.0033350.g005
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of Mn
2+ causes dissociation of the ADAM17/b1 integrin complex,
but at the same time Mn
2+ increased ADAM17 sheddase activity.
These data suggest that a5b1 integrin conformation indeed
regulates integrin binding to ADAM17 and the enzyme activity.
In our earlier studies, we determined the sheddase activity of
ADAM17 by Western blotting [11,12]. In order to detect the
presence of growth factors from the cell media successfully, we had
to concentrate the supernatant of a large number of mesangial
cells. To study that b1 integrin regulated ADAM17 sheddase
activity in mesangial cells we utilized a more sensitive method. We
employed alkaline phosphatase (AP)-tagged HB-EGF [31] because we
wanted to monitor small enzyme activity changes from a smaller
number of cells and we hoped to detect a more immediate
response to 5-HT compared to our earlier studies. Using AP-
tagged HB-EGF, we were able to repeat our previous observation:
5-HT induced significant increase in shedding of the growth
factor. To our disappointment, however, we still needed to
stimulate the cells for at least 30 min21 h with 5-HT in order to
see changes in growth factor shedding, even with this sensitive
method. We speculated that the reason for this ‘‘delayed release’’ is
that some of the growth factors internalize with the EGFR after
binding, or perhaps the cleaved growth factors stay bound to cell
surface proteoglycans [32]. Therefore, the amount of ‘‘released’’
growth factor can be very small, and a long incubation time is
needed in order to detect the shedded growth factor even using
this sensitive assay. Nonetheless, we were able to show that 5-HT
induced time-dependent release of HB-EGF. Further, our gene
silencing and overexpression studies confirmed that b1 integrin is
indeed an important negative regulator of ADAM17 activity in
kidney mesangial cells during GPCR activation. Interestingly,
changes in b1 integrin expression did not affect basal ADAM17
activity as dramatically as we expected. Overexpression of b1
integrin did not significantly decrease the basal activity of the
enzyme, but since our immunofluorescence data suggested that
most of ADAM17 present in resting mesangial cells are bound to
a5b1 integrin, it is highly possible that further increasing the
integrin level will have no further effect on ADAM17 activity. The
fact, that b1 integrin silencing only moderately increased
ADAM17 activity in unstimulated cells is more intriguing. Since
ADAM17 is a very important enzyme for the cell survival, it is
possible, that besides b1 integrin there are other important
regulatory proteins that control the enzyme activity. Removing b1
integrin from the ADAM17 complex can allow rearrangement of
regulatory molecules and/or binding of new ones. These
possibilities need to be further investigated in the future.
In summary, the data presented in this study provide evidence
that binding of a5b1 integrin to ADAM17 has an important role
in the activity regulation of the enzyme. Further, to our knowledge
this is the first paper to report that GPCR engagement leads to
ADAM17 activation through dissociation of an integrin from the
enzyme. This novel observation is an important step in our
understanding in how ADAM17 (or potentially other catalytically
active ADAMs) can be regulated by integrins. Further, since there
is increasing evidence for the pathophysiological role of ADAM17
in CKD and other metabolic and inflammatory diseases, we
suggest that targeting the integrin-binding of the enzyme can be
used to develop novel therapies for these disorders in the future.
Materials and Methods
Cell Culture
Ethics Statement. Primary rat mesangial cells were obtained
from cortical section of kidneys from 100–150 gram Sprague-
Dawley rats by collagenase treatment and a standard sieving
technique as described previously [33]. The kidneys were
harvested in accordance with the protocol specifically approved
for this study by the Institutional Animal Care and Use
Committees of the Medical University of South Carolina.
Cells were cultured in RPMI-1640 medium supplemented with
20% (v/v) fetal bovine serum (FBS) and antibiotics (100 units/ml
penicillin and 100 mg/ml streptomycin) at 37uC in a humidified
atmosphere of 95% air and 5% CO2. Cells were subcultured
weekly and used between passages 6–14. All cell culture reagents
were purchased from Invitrogen (Carlsbad, CA).
Co-Immunoprecipitation and Western Blotting
Mesangial cells were seeded into culture plates, grown to 80%
confluency and serum starved for 2 days in 0.5% (w/v) bovine
serum albumin (BSA)-containing medium. Cells were then treated
with vehicle or with 1 mM of 5-HT for 10 min. Cell were lysed
after stimulation in 1% Triton lysis buffer (Boston Bioproducts,
Ashland, MA) containing protease inhibitors (Protease inhibitor
cocktail set III, EMD Biosciences, San Diego, CA) and
phosphatase inhibitors (Halt
TM Phosphatase Inhibitor Cocktail,
Thermo Scientific, Rockford IL) on a rotating shaker at 4uC for
30 min. Equal protein amount (,1 mg) of cell lysates were
incubated overnight at 4uC with ADAM17-specific antibody
(MAB2129, R&D Systems, Minneapolis, MN). After incubation at
4uC for 1 h with protein G-agarose beads (Santa Cruz Biotech,
Santa Cruz, CA), immunoprecipitated protein complexes were
washed with lysis buffer and eluted with SDS-PAGE sample
buffer. Protein complexes were resolved by SDS-PAGE using
either 3–8% Tris-acetate gel or 4–12% Bis-Tris gel (Invitrogen,
Carlsbad, CA) as described before [34] and analyzed by
immunoblotting using 1:100 dilution of a5 integrin antibody (sc-
10729, Santa Cruz Biotechnology, Santa Cruz, CA) or 1:500
dilution of b1 integrin-specific antibody (sc-8978, Santa Cruz
Biotechnology, Santa Cruz, CA). Blots were then re-probed using
1:5,000 dilution of ADAM17-antibody (MAB2129, R&D Systems,
Minneapolis, MN). Immunoprecipitations with non-immune IgG
or protein G-agarose beads alone served as negative controls.
Immunofluorescence staining and Confocal Microscopy
Cells were grown on 35 mm lysine-coated glass-bottom culture
dishes (MatTek Corporation, Ashland, MA). After treatments with
1 mM of 5-HT, cells were fixed with freshly prepared 2%
paraformaldehyde in PBS containing 0.2% Triton X-100 for
15 min at room temperature. Nonspecific binding sites were
blocked with 1% bovine serum albumin in PBS for 1 h. Cells were
incubated with 1:100 dilution (2 mg/ml) of ADAM17-specific
antibody (sc-6416, Santa Cruz, Santa Cruz, CA) and with 1:50
dilution of a5b1 integrin antibody (MAB1969, Millipore, Billerica,
MA). Negative controls were incubated only with buffer. Incuba-
tions with 1:500 dilutions of Alexa Fluor-conjugated appropriate
secondary antibodies (Invitrogen, Carlsbad, CA) were performed in
blocking solution. Confocal microscopy was performed using a
Leica laser-scanning microscope (Wetzlar, Germany).
In situ proximity ligation assay (PLA)
We used the Doulink in situ PLA reagent from Olink
Biosciences (Uppsala, Sweden) to characterize endogenous protein
interactions according to the manufacturer’s recommendation.
Cells were grown on glass bottom culture dishes then treated and
handled as for immunofluorescence staining above. After incu-
bating with ADAM17 and a5b1 integrin antibodies for 1 h at
room temperature oligo-labelled anti-goat plus and anti-mouse
minus PLA probes were used as recommended by the manufac-
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antibody or with a5b1 integrin antibody only before incubation
with PLA probes. Samples were mounted with the Duolink
mounting medium. PLA images (fluorescence dots) were acquired
using a Leica laser-scanning microscope (Wetzlar, Germany) and
analyzed by ‘‘BlobFinder’’, a freeware developed by the Centre for
Image Analysis, Uppsala University, Sweden (http://www.cb.uu.
se/,amin/BlobFinder).
In Vitro Binding Assay
Direct binding of ADAM17 and integrins was analyzed using
capture-ELISA assay. ELISA plates were coated with 5 mg/ml of
a5b1 integrin antibody (Millipore, MAB1969), or with b1i n t e g r i n
antibody (Santa Cruz, sc-8978) in 50 mM Na2CO3 buffer (pH 9.6)
at4uC overnight. Plates werethenblocked with 5%(w/v) RIAgrade
BSA (Sigma-Aldrich, St. Louis, MO), then incubated with
recombinant human b1 integrin (H00003688-P01, Abnova, Taipei
City, Taiwan) or with purified a5b1 integrin (Millipore, Billerica,
MA) in Tris buffer (pH 7.4) containing 25 mM octyl-D-gluco-
pyranoside, 0.5 mM CaCl2, 1 mM MgCl2 and 0.5 mM MnSO4
overnight at 4uC. The next day, plates were washed and
recombinant human ADAM17 (cat#930-ADB, R&D Systems,
Minneapolis, MN), was added at concentrations indicated. After 3 h
of incubation at room temperature, His-probe horseradish perox-
idase (Thermo Scientific, Waltham, MA) was added as suggested by
the manufacturer for 15 min at room temperature. Peroxidase
activity as a measure of bound ADAM17 was determined using 1
step ultra TMB (3,39,5,59-tetramethylbenzidine) chromogenic sub-
strate according to the manufacturer’s recommendation (Thermo
Scientific, Waltham, MA). Reaction was terminated with 2 N
sulfuric acid and absorbance was read at 450 nm by a SpectraMax
M5 fluorescence plate reader (Molecular Devices, Sunnyvale, CA).
Fluorescence Enzyme Activity Assay
Recombinant ADAM17 was purchased from R&D Systems
(Minneapolis, MN) and purified, octyl-b-glucoside (OG) extracted
a5b1 integrin was from Millipore (Billerica, MA). Recombinant
ADAM17 (10 ng/well) was measured alone or ADAM17 was
combined with a5b1 integrin at a 1:1 and 1:10 molar ratio in OG
containing buffer (50 mM Tris, 150 mM NaCl, 25 mM OG,
1 mM CaCl2, 1 mM MgCl2 and 0.5 mM ZnSO4) in 96 well
plates. The quenched fluorogenic ADAM17 substrate MCA-Pro-
Leu-Ala-Gln-Ala-Val-Dpa-Arg-Ser-Ser-Ser-Arg-NH2 (EMD Bio-
sciences, San Diego, CA) was then added at a 6 mM final
concentration, and enzyme activity was measured as the rate of
change of relative fluorescence units (DRFUs
21) using a
Spectramax M5 spectrofluorometer (Molecular Devices, Sunny-
vale, CA) with excitation at 320 nm and emission at 405 nm.
Alkaline Phosphatase (AP)-HB-EGF Shedding Assay
Mesangial cells were seeded into 12-well tissue culture plates and
transfected with alkaline phosphatase (AP)-tagged HB-EGF ex-
pressing construct alone or in combination with either b1 integrin-
expressing vector (Genecopoeia, Rockville, MD) or with b1 integrin
siRNA (Dharmacon, Lafayette, CO) using Dharmafect Duo
reagent (Dharmacon, Lafayette, CO) as directed by the manufac-
turer. As negative controls, we used GFP-expressing vector and
non-targeting siRNA, respectively. Two days after transfection the
cells were stimulated with 1 mM 5-HT for the indicated length of
time, and growth factor release was quantified by measuring the AP
activity of the medium using a sensitive alkaline phosphatase
substrate (Attophos, Roche, Indianapolis, IN) and the SpectraMax
M5 fluorescence plate reader (Molecular Devices, Sunnyvale, CA).
Integrin conformation studies
For integrin conformation studies cells were incubated in 1 mM
MnCl2-containing PIPES buffer (50 mM pH 7.4) for 2 minutes.
Cells were then lyzed in OG lysis buffer (50 mM Tris pH 7.4,
25 mM octyl-D-glucopyranoside and 150 mM NaCl) containing
protease inhibitors (Protease inhibitor cocktail set III, EMD
Biosciences, San Diego, CA). ADAM17/integrin complexes were
immunoprecipitated using ADAM17 antibody and analyzed in
SDS-PAGE followed by ADAM17 and b1 integrin Western
blotting as described above. For shedding experiments, mesangial
cells were seeded into 12 well plates and transfected with the AP-
HB-EGF. The cells were washed with PBS and incubated in
50 mM PIPES buffer (pH 7.4) with or without 1 mM Mn
2+ for
1 h and HB-EGF shedding was measured as described above.
Statistical Analysis
For data analysis, Student’s t-test and ANOVA followed by
Newmann-Keul post hoc comparison were performed using Prism
Statistics Software (GraphPad, La Jolla, CA). P values ,0.05 were
regarded as statistically significant.
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